IHH Healthcare Berhad has invested in Intellect , Asia ’ s leading digital mental health company . The investment will accelerate Intellect ’ s growth across the region . Founded in 2019 , Intellect has grown exponentially in recent years to serve more than three million users in over 20 countries on its platform , including Malaysia , Singapore , India and Hong Kong . IHH Healthcare , listed on Bursa Malaysia , will co-develop and customise digital mental health programmes with Intellect for its patients , corporate clients , and staff .
In a pilot initiative , maternity patients from Gleneagles Hospital Singapore will be among the first from the IHH Healthcare ’ s network to enjoy Intellect ’ s offerings . IHH Healthcare group chief strategy and business
|
development officer Ashok Pandit said : “ Mental and physical health are equally important components of total well-being .
“ Mental health issues affect one in every four persons . We are pleased to invest in a market leader in this rapidly growing category , to boost their growth and enhance access to millions more people who require support , care or treatment ,” he said in a recent statement .
Intellect ’ s mental health services include telehealth coaching , clinical therapy , psychiatry , self-guided cognitive behavioural therapy-based programmes , urgent distress support , and mental health screening – all done either virtually via the Intellect platform or in person at an Intellect clinic .
Intellect Co-Founder and CEO
|
Theodoric Chew said the company was excited to partner with IHH Healthcare to form a game-changing alliance to transform mental health care across Asia effectively .
“ Our mission to scale mental healthcare accessibly to everyone , every day , will be significantly enabled through this partnership , combining IHH Healthcare ’ s global healthcare network with our technology and mental health focus ,” he said .
The cost of treating mental issues is expected to reach around US $ 6 trillion globally by 2030 . Within the Asia Pacific , the digital mental health market for business-to-business alone is projected to grow from US $ 3.1 billion in 2021 to US $ 8.5 billion by 2026 , with increasing demand from corporates , insurers and consumers .
IHH Healthcare is the first strategic
|
healthcare investor in Intellect , which also has the backing of established investors and venture funds . Intellect raised a US $ 20 million Series A funding round in 2022 , led by Tiger Global , and counts many leading investors as backers , including Y Combinator , Insignia Ventures , HOF Capital , MS & AD Ventures , Singtel Innov8 , K3 Ventures , East Ventures , and many more . |
INSOMNIA is often characterised by problems falling or staying asleep , which can affect one ’ s daytime functioning and quality of life . The incidence of insomnia is rising and to combat this , appropriate education , awareness initiatives , and therapies must be provided to individuals needing them .
Determined to provide Malaysians with a treatment , Eisai ( Malaysia ) Sdn Bhd , recently launched its new treatment for insomnia , Dayvigo , to combat their sleepless nights .
Held in conjunction with World Sleep Day , Eisai Malaysia hopes to spread awareness of sleep health by emphasising the importance of delivering an effective treatment for a good night ’ s sleep . With the launch of Dayvigo , Eisai Malaysia is singleminded
|
to treat insomnia in order for Malaysians to lead a good quality of life while preventing other chronic diseases that may emerge as a result of sleep deprivation .
Sharing the mutual purpose of advocating sleep health among Malaysians , the launch witnessed the participation of Prof Ng Chong Guan , Consultant Psychiatrist and Treasurer of Malaysian Psychiatric Association and Dr Hazli Zakaria , Founder of Alaminda Healthcare Berhad who shared the platform to exchange thoughts and discourse addressing the key concerns surrounding insomnia .
Kam Ai Teng , Managing Director of Eisai Malaysia shared that sleep is vital especially for our bodies to function effectively daily - yet it is a subject neglected by many .
|
“ We are thrilled to bring Dayvigo into the market , providing an additional treatment option for people with insomnia . Insomnia is a severe health issue that affects millions of people worldwide . We fail to realise the severity of insomnia until it ’ s too late , and people now need to know that it can arise at different phases of the sleep cycle and induce daytime impairments such as fatigue , daytime sleepiness , mood changes , and other symptoms .”
“ After thorough research , our team of researchers and scientists have worked tirelessly to develop a product that is effective to help individuals who struggle with insomnia get the restful sleep they need to improve their overall health .”
As Dual Orexin Receptor Antagonist
|
Kam Ai Teng
( DORA ) treatment in Malaysia , Dayvigo has been rigorously tested in clinical trials and is highly effective in helping individuals fall asleep fast , with minimal impacts on next-morning alertness or next-day function . Dayvigo is a novel class of treatment that facilitates individuals to sleep by suppressing wakefulness . – The Health
|